Alserawan Leticia, Peñacoba Patricia, Orozco Echevarría Sandra Elizabet, Castillo Diego, Ortiz Esther, Martínez-Martínez Laura, Moga Naranjo Esther, Domingo Pere, Castellví Ivan, Juárez Cándido, Mariscal Anaís
Department of Immunology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain.
Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Diagnostics (Basel). 2021 Oct 27;11(11):1998. doi: 10.3390/diagnostics11111998.
It is essential to find new biomarkers for severity stratification of patients with coronavirus disease (COVID-19). Growth differentiation factor 15 (GDF-15) is upregulated in pathological conditions that involve inflammation and/or oxidative stress. We determined circulating levels of GDF-15 and correlated them with clinical and laboratory parameters reflecting severity in 84 patients with COVID-19, finding that GDF-15 levels were higher in both patients than in 20 healthy controls and were higher in patients with poorer respiratory function. GDF-15 levels also correlated with interleukin-6, C-reactive protein, ferritin and D-dimer levels and with neutrophilia and lymphopenia. Of all the analysed biomarkers, GDF-15 showed the best area under the receiver operating characteristics curve in identifying patients with poor respiratory function. In conclusion, our data support GDF-15 as a biomarker associated with pulmonary impairment in COVID-19 and so can potentially be useful in stratifying COVID-19 cases by severity.
寻找新型生物标志物用于冠状病毒病（COVID-19）患者的严重程度分层至关重要。生长分化因子15（GDF-15）在涉及炎症和/或氧化应激的病理状况下会上调。我们测定了84例COVID-19患者的循环GDF-15水平，并将其与反映严重程度的临床和实验室参数进行关联，发现COVID-19患者的GDF-15水平高于20名健康对照者，且呼吸功能较差的患者中GDF-15水平更高。GDF-15水平还与白细胞介素-6、C反应蛋白、铁蛋白和D-二聚体水平以及中性粒细胞增多和淋巴细胞减少相关。在所有分析的生物标志物中，GDF-15在识别呼吸功能差的患者时，显示出最佳的受试者工作特征曲线下面积。总之，我们的数据支持GDF-15作为与COVID-19肺部损伤相关的生物标志物，因此可能有助于按严重程度对COVID-19病例进行分层。
